<DOC>
	<DOCNO>NCT00217529</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving erlotinib together docetaxel carboplatin may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose erlotinib give together docetaxel carboplatin see well work treat patient newly diagnose stage III stage IV ovarian epithelial , primary peritoneal cavity , fallopian tube cancer .</brief_summary>
	<brief_title>Erlotinib , Docetaxel , Carboplatin Treating Patients With Newly Diagnosed Stage III Stage IV Ovarian Epithelial , Primary Peritoneal Cavity , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) erlotinib administer combination docetaxel carboplatin front-line therapy patient newly diagnose stage III IV ovarian epithelial , primary peritoneal cavity , fallopian tube cancer . Secondary - Determine toxicity maintenance therapy erlotinib administer front-line therapy patient . - Determine proportion patient able receive full schedule treatment course . - Determine objective response rate patient measurable evaluable disease treat regimen . - Determine progression-free overall survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study erlotinib . - Front-line therapy : Patients receive docetaxel IV 1 hour carboplatin IV 30 minute day 1 , pegfilgrastim subcutaneously day 2 , oral erlotinib daily day 3-16 . Treatment repeat every 21 day 6 course . Cohorts 5 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 5 patient experience dose-limiting toxicity . - Maintenance therapy : Beginning 3-4 week completion front-line therapy , patient stable respond disease receive oral erlotinib daily 12 month . After completion study treatment , patient follow every 6 month 1 year periodically thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , primary peritoneal cavity , fallopian tube cancer Stage III IV disease The following histologic epithelial cell type allow : Serous adenocarcinoma Mucinous adenocarcinoma Clear cell adenocarcinoma Endometrioid adenocarcinoma Mixed epithelial carcinoma Undifferentiated carcinoma Transitional cell carcinoma Malignant Brenner tumor Adenocarcinoma otherwise specify Must undergone appropriate surgery ovarian epithelial , primary peritoneal cavity , fallopian tube cancer within past 6 week No borderline ovarian tumor low malignant potential PATIENT CHARACTERISTICS : Age 18 Performance status GOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal Meets 1 follow criterion : Alkaline phosphatase ( AP ) normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal No hepatic disease would preclude study participation Renal Creatinine ≤ 2.0 mg/dL Creatinine clearance &gt; 50 mL/min No renal disease would preclude study participation Cardiovascular LVEF ≥ low limit normal* No poorly control arrhythmia No unstable coronary artery disease No myocardial infarction within past year NOTE : *LVEF evaluation perform patient require Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No peripheral neuropathy ≥ grade 2 No nonmalignant systemic disease would preclude study participation No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No medical , social , psychosocial factor would preclude study participation No psychiatric addictive disorder would preclude give informed consent No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix breast PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy malignancy Chemotherapy No prior chemotherapy malignancy Endocrine therapy No prior hormonal therapy malignancy Radiotherapy No prior radiotherapy malignancy Surgery See Disease Characteristics No plan interval cytoreductive surgery Secondlook surgery allow Other More 1 year since prior experimental investigational therapy No concurrent therapeutic anticoagulation warfarin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>Brenner tumor</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
</DOC>